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Evaluation of the Xpert Clostridium difficile Assay for 
the Diagnosis of Clostridium difficile Infection
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and Yunsop Chong, Ph.D.
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Infection with Clostridium difficile is a growing concern because of the increasing preva-
lence and spread of nosocomial infections. Emergence of the hypervirulent 027/NAP1/BI 
strain is also notable. Existing diagnostic methods have low sensitivity or are time-consum-
ing. Therefore, establishing a rapid and accurate microbiological diagnostic assay is need-
ed. We evaluated the Xpert C. difficile assay (Xpert CD assay; Cepheid, USA) to detect 
toxigenic C. difficile. This assay is a real-time multiplex PCR assay that can be used to de-
tect toxigenic C. difficile strains and differentiate the C. difficile presumptive 027/NAP1/BI 
strain. A total of 253 loose stool specimens were collected and toxigenic cultures, VIDAS C. 
difficile A & B assays (VIDAS CDAB assay; bioMérieux, France), and the Xpert CD assay 
were performed. In comparison to toxigenic cultures, the sensitivity, specificity, and posi-
tive and negative predictive values were 100%, 94.6%, 83.1%, and 100%, respectively, for 
the Xpert CD assay and 40.8%, 98.0%, 100%, and 88.9%, respectively, for VIDAS CDAB 
assay. Because of the low prevalence of the PCR ribotype 027 in Korea, the evaluation of 
the usefulness of the Xpert CD assay for screening for the 027 strain was limited. The 
Xpert CD assay provides great sensitivity in diagnosing toxigenic C. difficile infection. In 
addition, this method has excellent usability because it is simple and fast.
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Clostridium difficile is the leading cause of antibiotic-associated 
diarrhea and pseudomembranous colitis. The increasing preva-
lence and severity of healthcare-associated C. difficile infections 
(CDI) is of great concern [1]. Moreover, emergence and spread 
of the hypervirulent 027/NAP1/BI strain of C. difficile have been 
reported in North America and Europe [2-4]. The characteristics 
of the PCR ribotype 027 strain are production of the C. difficile 
binary toxin (CDT), as well as toxin A/B, and a single nucleotide 
deletion at position 117 in the tcdC gene [4]. The diagnosis of 
CDI should be based on a combination of symptoms and a pos-
itive stool test result for C. difficile toxins or toxigenic C. difficile 
[5]. Enzyme immunoassays rapidly detect toxins A and B, but 
their sensitivity varies greatly among the various products [6]. 
Toxigenic cultures and cytotoxin assays are considered as gold 
standard methods for the detection of toxigenic C. difficile, but 
toxigenic cultures that combine anaerobic cultures and detec-
tion of toxin A and B production take at least 48 hr to complete. 
Cytotoxin assays using cultured cells are also time-consuming 
and costly, making them unsuitable for routine laboratory diag-
nosis. Therefore, a rapid and more accurate microbiological di-
agnostic assay is highly needed for providing optimal patient 
care and controlling the spread of infections in hospitals. 
 The Xpert C. difficile assay (Xpert CD assay; Cepheid, Sunny-
vale, CA, USA) is a real-time multiplex PCR assay performed 
using the GeneXpert Dx system. The assay uses primers tar-
geted to the cytotoxin gene (tcdB), binary toxin genes (cdtA and 
cdtB), and a single nucleotide deletion at position 117 in the 
tcdC gene. As a result, the Xpert CD assay can detect toxigenic 
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C. difficile strains and differentiate C. difficile presumptive 027/
NAP1/BI. We evaluated the Xpert CD assay for rapidity and ac-
curacy in diagnosing CDI. 
 A total of 253 consecutive loose stool specimens were col-
lected in a stool specimen container from suspected CDI pa-
tients from April to June 2011, in a tertiary hospital. For toxigenic 
cultures, alcohol-shocked stool specimens were inoculated on 
C. difficile selective agar (CDSA; Becton, Dickinson and Com-
pany, Sparks, MD, USA) and incubated at 37°C in an anaerobic 
chamber (Forma scientific, Marietta, OH, USA) for 48 hr. Sus-
pected C. difficile colonies were used to make a gram-stained 
smear to observe typical morphology. The species were identi-
fied by using the ATB 32A system (bioMérieux, Marcy l’Etoile, 
France). The identified C. difficile isolates were used to detect 
tcdA repetitive regions, tcdB as well as cdtA and cdtB genes, 
following the previously described PCR method [7] and using 
the PCR primers listed in Table 1. 
 Xpert CD assays were performed according to the manufac-
turer’s instructions. A stool specimen was transferred to a vial 
containing a buffer solution by using a sterile swab. The vial was 
vortexed, and the solution was then transferred to a cartridge. 
The test was run on the GeneXpert DX module. The results 
were reported as C. difficile-positive 027/NAP1/BI presumptive 
negative, C. difficile-positive 027/NAP1/BI presumptive positive, 
C. difficile-negative, invalid, error, or no result. The test was re-
peated if the result was “invalid,” “error,” or “no result.” Se-
quencing of the tcdC gene was performed on isolates that were 
positive for the presumptive 027/NAP1/BI strain. PCR ribotyping 
and tcdC sequencing were performed in accordance with previ-
ously described methods [8, 9] for isolates that tested positive 
for binary toxin genes in the Xpert CD assay in order to confirm 
the results.
 VIDAS C. difficile A & B assays (VIDAS CDAB assay; bioMéri-
eux) were performed according to the manufacturer’s instruc-
tions. Test results are presented as positive, negative, or equivo-
cal for toxins A and/or B. Specimens with equivocal results were 
retested once.
 By anaerobic culture, 55 of 253 (21.7%) specimens yielded C. 
difficile isolates. Of these, 49 (19.4%) isolates were confirmed to 
be tcdB-positive (Table 2). 
Table 1. Sequences of the PCR primers used in this study 
Test Target Primer Sequence (5’→3’)
Refer-
ence
Toxin gene tcdA rep NK9 CCA CCA GCT GCA GCC ATA [7]
  detection NK11 TGA TGC TAA TAA TGA ATC TAA AAT GGT AAC
tcdB NK104 GTG TAG CAA TGA AAG TCC AAG TTT ACG C
NK105 CAC TTA GCT CTT TGA TTG CTG CAC CT
cdtA cdtApos TGA ACC TGG AAA AGG TGA TG
cdtArev AGG ATT ATT TAC TGG ACC ATT TG
cdtB cdtBpos CTT AAT GCA AGT AAA TAC TGA G
cdtBrev AAC GGA TCT CTT GCT TCA GTC
Ribotyping 16S-23S CD1 GCG CCC TTT GTA GCT TGA CC [8]
  rRNA CD1445 CTG GGG TGA AGT CGT AAC AAG G
tcdC tcdC PaL15 TCT CTA CAG CTA TCC CTG GT [9]
  sequencing PaL16 AAA AAT GAG GGT AAC GAA TTT 
Abbreviations: tcdA rep, toxin A gene repetitive region; tcdB, toxin B gene; 
cdtA and cdtB, binary toxin genes. 
Table 2. Evaluation of Xpert Clostridium difficile and VIDAS Clostridium difficile A & B assays for the detection of toxigenic Clostridium diffi-
cile isolates 
Toxigenic culture (N. of isolates)
N. of isolates
Xpert CD VIDAS-CDAB
B+,
CDT-,
027-
B+,
CDT+,
027-
B+,
CDT+,
027+
B-,
CDT-,
027-
Error
A and/or B
Positive
A and/or B
Negative
Equivocal
Growth (55) A+B+/A-B+, CDT- (45) 44 1 0 0 0 19 23 3
A+B+, CDT+ (4) 0 3  1* 0 0 1 2 1
A-B-, CDT- (6) 2 0 0 4 0 0 5 1
No growth (198) 8† 0 0 189  1‡ 0 195 3
Total (253) 54 4 1 193 1 20 225 8
*One presumptive 027/NAP1/BI strain identified as ribotype 078 on PCR ribotyping as well as a 39-base pair deletion and a point mutation at position 184 
in tcdC; †Four specimens showed positive results by enrichment culture; ‡One “error” in the Xpert CD assay: no growth on anaerobic culture and negative on 
VIDAS-CDAB.
Abbreviations: Xpert CD, Cepheid Xpert Clostridium difficile assay; VIDAS-CDAB, VIDAS Clostridium difficile Toxin A&B assay; A, toxin A; B, toxin B; CDT, C. 
difficile binary toxin; 027, presumptive 027/NAP1/BI strain.
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 The Xpert CD assay detected tcdB in all 49 isolates identified 
as tcdB-positive by toxigenic culture (sensitivity 100%, Table 3). 
For 8 specimens that tested positive in the Xpert CD assay but 
were negative upon toxigenic culture, an enrichment culture 
was performed using cycloserine-cefoxitin fructose broth sup-
plemented with 0.1% sodium taurocholate (TCCFB). Four of 
these eight specimens yielded a positive result for toxigenic C. 
difficile (Table 4). On the basis of analyses of other samples 
from the same patients, we suspect that at least 2 samples were 
contaminated with residual DNA [10]. In 3 undetermined cases, 
possible explanations for the discrepant results are residual 
DNA from prior CDI, false-positive PCR result, or true-positive 
PCR result. 
 Compared to the toxigenic culture, the sensitivity, specificity, 
and positive and negative predictive values were 100%, 94.6%, 
83.1%, and 100%, respectively, for the Xpert CD assay, and 
40.8%, 98.0%, 100%, and 88.9%, respectively, for the VIDAS 
CDAB assay (Table 3). The overall agreement between the Xpert 
CD assay and toxigenic culture was 95.7%. Data from the en-
richment culture were not included in the calculation of sensitiv-
ity, specificity, and positive and negative predictive values. One 
“error” case of the Xpert CD assay and 8 “equivocal” cases of 
the VIDAS CDAB assay were included in the calculation of as-
say performance (Table 2). 
 Binary toxin genes (cdtA and cdtB) were detected in 5 speci-
mens by the Xpert CD assay, and 1 of them showed a 027/
NAP1/BI presumptive positive result. The binary toxin genes 
were confirmed by toxin gene-specific PCR, PCR ribotyping, 
and tcdC sequencing. Four (including one 027/NAP1/BI pre-
sumptive positive isolate) of the 5 isolates revealed positive re-
sults for binary toxin genes. In addition, all 4 isolates showed an 
identical pattern to that of ribotype 078 and no deletion at posi-
tion 117 of the tcdC gene. All ribotype 078 strains showed a 39-
base pair deletion and a point mutation at position 184 in the 
tcdC gene [11].
 Similar to a previous study, the evaluation of the usefulness of 
the Xpert CD assay for screening for the 027 strain was limited 
in this study due to the low prevalence of binary toxin-producing 
Table 3. Assay performance of Xpert Clostridium difficile and VIDAS Clostridium difficile A & B assays for the detection of toxigenic Clos-
tridium difficile isolates compared with toxigenic culture
Assay
Assay performance (95% confidence interval)*
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Xpert CD 100 94.6 (91.5-97.7) 83.1 (73.5-92.7) 100
VIDAS-CDAB 40.8 (27.0-54.6) 98.0 (96.1-99.9) 100 88.9 (84.8-93.0) 
*Sensitivity, specificity, PPV, and NPV are calculated as follows (×100): sensitivity, (number of true-positive assay results)/(sum of toxigenic culture-positive 
results); specificity, (number of true-negative assay results)/(sum of toxigenic culture-negative results); PPV, (number of true-positive assay results)/(sum of 
true-positive and false-positive assay results); NPV, (number of true-negative assay results)/(sum of true-negative and false-negative assay results). 
Abbreviations: Xpert CD, Xpert Clostridium difficile assay; VIDAS-CDAB, VIDAS Clostridium difficile A & B assay; PPV, positive predictive value; NPV, negative 
predictive value.
Table 4. Discordant results and further analysis of Xpert Clostridium difficile and toxigenic culture*  
Sample 
No. 
Results
Comment Possible explanationEnrichment 
culture
tcdB 
PCR
VIDAS
-CDAB
1 Growth Negative Negative Previous C. difficile positive (toxigenic culture) Residual DNA
2 Growth Negative Negative Only one sample submitted Undetermined†
3 Growth Negative Equivocal Only one sample submitted Undetermined
4 Growth Positive Negative Enrichment culture C. difficile positive (toxigenic culture) True-positive PCR
5 Growth Positive Negative Enrichment culture C. difficile positive (toxigenic culture) True-positive PCR
6 Growth Positive Negative Enrichment culture C. difficile positive (toxigenic culture) True-positive PCR
7 No growth Not done Negative Previous C. difficile positive (toxigenic culture) Residual DNA
8 No growth Not done Negative Only one sample submitted Undetermined
*All samples with initially no growth on anaerobic culture and Clostridium difficile-positive 027/NAP1/BI presumptive negative on Xpert CD assay; †False-pos-
itive PCR, residual DNA, or true-positive PCR.
Abbreviations: Xpert CD, Cepheid Xpert Clostridium difficile assay; VIDAS-CDAB, VIDAS Clostridium difficile Toxin A & B assay. 
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C. difficile strains (3.8% to 7.1%) and PCR ribotype 027 (0.6%) 
in Korea [12, 13]. A previously published study reported that the 
agreement between the Xpert CD assay and PCR-ribotyping was 
93% [10]. Other studies reported discordant results for the pre-
sumptive 027/NAP1/BI strain between the Xpert CD assay and 
conventional typing and sequencing [14, 15]. These authors re-
ported 1 ribotype 053 strain [15], 1 strain similar to the 078 strain 
[14], and 6 strains of unknown type. Ribotype 078 is the most 
frequent type present as a binary toxin-positive strain in Korea 
[12, 13]. Therefore, results of the presumptive 027/NAP1/BI 
strain must be interpreted with caution, particularly in Korea, 
where the prevalence of ribotype 027 is low. 
 The most significant advantage of the Xpert CD assay is its 
rapidity and simplicity. A loose stool specimen can be directly 
used, and the assay takes only 45 min. 
 In conclusion, the Xpert CD assay is a reliable method for de-
tecting toxigenic C. difficile directly from stool specimens and 
provides greater sensitivity than an enzyme immunoassay.  
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